Hudson Bay Capital Management’s SpringWorks Therapeutics SWTX Stock Holding History

Hudson Bay Capital Management’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-547,010	Closed	-$25.7M	–	1656
2025 Q2	$25.7M	Buy	547,010 +13,401	+3%	+$596K	0.09%	176
2025 Q1	$23.5M	Buy	533,609 +478,109	+861%	+$22M	0.07%	242
2024 Q4	$2.01M	Buy	55,500 +17,700	+47%	+$618K	0.01%	662
2024 Q3	$1.21M	Buy	+37,800	New	+$1.41M	﹤0.01%	639

Other funds holding SWTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Hudson Bay Capital Management's SWTX Position: Q3 2025 in Review

Hudson Bay Capital Management sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 547,010 shares — an estimated $25.7M sold.

Hudson Bay Capital Management first reported a position in SWTX in Q3 2024 and held it in 4 quarters. The position peaked at $25.7M in Q2 2025. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.

Hudson Bay Capital Management reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
Hudson Bay Capital Management sold 547,010 SpringWorks Therapeutics shares in Q3 2025, an estimated $25.7M.
Hudson Bay Capital Management first reported a position in SpringWorks Therapeutics in Q3 2024 and held it in 4 quarters.
Hudson Bay Capital Management's SpringWorks Therapeutics position peaked at $25.7M in Q2 2025.
3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.

Based on Hudson Bay Capital Management's 13F filing for Q3 2025, filed 13 Nov 2025.